NasdaqGS - Nasdaq Real Time Price USD

Indivior PLC (INDV)

16.97

-0.37

(-2.13%)

At close: May 17 at 4:00 PM EDT

16.97

0.00

(0.00%)

After hours: May 17 at 4:00 PM EDT

Indivior PLC (INDV) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ...

Despite facing cyberattack disruptions, Indivior reports robust revenue growth and reaffirms full-year guidance.

GuruFocus.com 22 days ago

INDV
-2.13%
Why Indivior PLC (LON:INDV) Looks Like A Quality Company

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Simply Wall St. 22 days ago

INDV
-2.13%
Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates

Indivior (INDV) delivered earnings and revenue surprises of -2.63% and 5.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 23 days ago

INDV
-2.13%
UPDATE 1-UK-listed drugmaker Indivior seeks shareholder nod for US listing

UK-listed drugmaker Indivior plans to seek shareholder approval next month for a primary listing in the United States, the company said on Thursday, which would add it to a growing list of firms leaving the London stock market. Indivior had, in February, announced its intent to shift its listing by the middle of the year to the U.S., which, it argued, reflected its growth opportunities as its proprietary treatments are U.S.-centred and U.S.-based investors account for nearly 50% of its overall shareholder base. The list of UK-based companies that have already listed in the United States includes ARM, the UK's biggest chip company, as well as building supplies firm CRH and plumbing equipment company Ferguson.

Reuters 23 days ago

INDV
-2.13%
Indivior Confirms Plan to Switch Listing From London to New York

(Bloomberg) -- Indivior Plc has confirmed plans to switch its primary listing to New York this summer, and will ask shareholders to approve the decision next month. Most Read from BloombergMalaysia in Talks With Tycoons on Casino to Revive $100 Billion Forest CityBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsUS Economy Slows and Inflation Jumps, Damping Soft-Landing HopesZuckerberg Asks for Patience as Meta’s AI Push Spooks MarketHow to Get a Meeting With the UAE’s $1.

Bloomberg 23 days ago

INDV
-2.13%
Indivior Announces Q1 2024 Financial Results

Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.

PR Newswire 23 days ago

INDV
-2.13%
Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?

Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks last month

INDV
-2.13%
USNA
Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Indivior PLC (INDV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks last month

INDV
-2.13%
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced respiratory depression, which is the major cause of deaths due to opioid overdose. The study, "Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone", was published in the Journal of Clinical Pharmacology (Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers:

PR Newswire 2 months ago

INDV
-2.13%
Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia

Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.

Zacks 2 months ago

VNDA

ANIP

INDV
-2.13%
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata

The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.

Zacks 2 months ago

NKTR

INDV
-2.13%
VNDA
Zacks.com featured highlights Modine Manufacturing, Indivior and Interface

Modine Manufacturing, Indivior and Interface have been highlighted in this Screen of The Week article.

Zacks 2 months ago

MOD

INDV
-2.13%
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat

Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.

Zacks 2 months ago

NKTR

INDV
-2.13%
VNDA
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.

Zacks 2 months ago

ARCT

VNDA

KNSA
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.

Zacks 2 months ago

MIRM

VNDA

INDV
-2.13%
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

PR Newswire 2 months ago

INDV
-2.13%
Earnings Update: Indivior PLC (LON:INDV) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

The investors in Indivior PLC 's ( LON:INDV ) will be rubbing their hands together with glee today, after the share...

Simply Wall St. 2 months ago

INDV
-2.13%
Health Care Roundup: Market Talk

1632 GMT – Falling interest rates in Brazil bode well for local shares, says Raphael Luscher, a portfolio manager at Vontobel The central bank has been cutting rates since August, as inflation slows. Luscher also likes Uruguay-based e-commerce giant Mercado Libre, for which Brazil is a key market. “Indivior Switching to a U.S. Listing Makes Sense But Would Be a Blow to U.K. — Market Talk,” at 1229 GMT, incorrectly said Indivior was a FTSE 100 company.

The Wall Street Journal 2 months ago

INDV
-2.13%
Fresh blow for London market as drug maker joins exodus to New York

Indivior, the British drug maker, is to ditch its primary listing on the London Stock Exchange for New York in the latest blow to the Square Mile.

The Telegraph 2 months ago

INDV
-2.13%
UPDATE 2-Drugmaker Indivior consults on moving primary listing from London to US

UK-listed drugmaker Indivior Plc has begun consulting shareholders on shifting its primary listing to the United States by the middle of this year, it said on Thursday, after reporting a 27% jump in annual profit. If Indivior moves its primary listing, it would join a growing list of companies leaving London, where lower valuations compared with the United States have left Britain struggling to prevent companies exiting and to lure IPOs. It said it would maintain its secondary listing in London.

Reuters 2 months ago

INDV
-2.13%

Performance Overview

Return	INDV	FTSE 100
YTD	+11.13%	+8.88%
1-Year	-10.31%	+8.63%
3-Year	+723.79%	+19.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Indivior PLC (INDV)

Indivior PLC (INDV) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ...

Why Indivior PLC (LON:INDV) Looks Like A Quality Company

Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates

UPDATE 1-UK-listed drugmaker Indivior seeks shareholder nod for US listing

Indivior Confirms Plan to Switch Listing From London to New York

Indivior Announces Q1 2024 Financial Results

Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?

Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia

Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata

Zacks.com featured highlights Modine Manufacturing, Indivior and Interface

Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

Earnings Update: Indivior PLC (LON:INDV) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Health Care Roundup: Market Talk

Fresh blow for London market as drug maker joins exodus to New York

UPDATE 2-Drugmaker Indivior consults on moving primary listing from London to US

Performance Overview